Octavia Wealth Advisors LLC acquired a new stake in Vale S.A. (NYSE:VALE – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 11,305 shares of the basic materials company’s stock, valued at approximately $101,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Vale by 6.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 7,951,020 shares of the basic materials company’s stock worth $92,868,000 after purchasing an additional 468,432 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Vale during the third quarter worth about $1,126,000. Bank of Montreal Can increased its position in Vale by 274.4% during the third quarter. Bank of Montreal Can now owns 162,453 shares of the basic materials company’s stock worth $1,915,000 after buying an additional 119,061 shares during the last quarter. Bridgewater Associates LP raised its stake in Vale by 723.2% in the third quarter. Bridgewater Associates LP now owns 2,035,477 shares of the basic materials company’s stock valued at $23,774,000 after buying an additional 1,788,205 shares during the period. Finally, Polar Asset Management Partners Inc. acquired a new stake in shares of Vale in the third quarter valued at approximately $1,422,000. 21.85% of the stock is owned by institutional investors.
Vale Price Performance
Shares of NYSE VALE opened at $8.86 on Thursday. The business has a fifty day moving average price of $9.26 and a two-hundred day moving average price of $10.22. The stock has a market capitalization of $40.08 billion, a PE ratio of 4.10, a P/E/G ratio of 0.28 and a beta of 0.92. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.91 and a quick ratio of 0.58. Vale S.A. has a fifty-two week low of $8.38 and a fifty-two week high of $14.47.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on VALE. Jefferies Financial Group decreased their target price on Vale from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, January 6th. UBS Group lowered shares of Vale from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $14.00 to $11.50 in a research report on Monday, November 11th. Barclays cut their target price on shares of Vale from $16.00 to $15.25 and set an “overweight” rating for the company in a research note on Wednesday, December 4th. StockNews.com began coverage on shares of Vale in a research note on Friday, December 13th. They issued a “buy” rating on the stock. Finally, Morgan Stanley downgraded shares of Vale from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $14.50 to $11.30 in a research report on Thursday, December 12th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.89.
Check Out Our Latest Research Report on Vale
Vale Company Profile
Vale SA, together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally. The company operates through Iron Solutions and Energy Transition Materials segments. The Iron Solutions segment produces and extracts iron ore and pellets, manganese, and other ferrous products; and provides related logistic services.
See Also
- Five stocks we like better than Vale
- Retail Stocks Investing, Explained
- Oracle Announces Game-Changing News for the AI Industry
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Vale Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vale and related companies with MarketBeat.com's FREE daily email newsletter.